Development and Optimization of a Multi-Class, Multi
Transcription
Development and Optimization of a Multi-Class, Multi
Development and Optimization of a Multi-Class, Multi-Residue Method for Veterinary Drug Analysis in Infant Formula Ingredients and Products Hui Zhao, John Zulkoski, Azeem Hasan and Katerina Mastovska Nutritional Chemistry and Food Safety, Covance Laboratories Inc., Madison, WI, USA [email protected], [email protected] Method Development Plan A modern multi-class, multi-residue method for detection, identification and quantitation of veterinary drugs using liquid chromatographytandem mass spectrometry (LC-MS/MS) is a highly effective approach for residue monitoring with the ultimate goal of protecting consumers from potentially unsafe exposure to drug residues in foods of animal origin (milk, meat, poultry, seafood, fish, egg and honey). In this study, we developed and optimized a method for over 150 compounds belonging to a variety of veterinary drug classes, including amphenicols, anthelmintics, antibiotics (beta-lactams – penicillins and cephalosporins, lincosamides, macrolides, quinolones, sulfonamides, tetracyclines, and others), antimicrobial growth promoters, antiprotozoals, beta-agonists, coccidiostats, dyes, NSAIDs, and tranquilizers. Infant formula was chosen to establish a robust, efficient and reliable method for screening, identification and quantitation of the included veterinary drug residues. MRM (dMRM) Acquisition Method Optimization Optimization of MS/MS conditions for individual compounds ▶ Mass spectrometer: Agilent® Triple Quadrupole 6495A MS/MS Optimization of LC conditions Main Phases Introduction Development of the final LC-MS/MS method the best two MRMs for the method Sample preparation procedure development and optimization ▶ Verify the selectivity for the final sample preparation procedure for multiple matrices Validation, data acceptance criteria and implementation in routine analysis Optimization of MS/MS Conditions for Individual Compounds Modern Multi-Class, Multi-Residue Method Using LC-MS ▶ Product ion scans ▶ Selection of MRMs and collision energy optimization ▶ Up to 10 MRMs per analyte Benefits Example: Sulfadoxin, m/z 311.1 ▶ Cost-effective ▶ Time-effective ▶ Selective detection of individual analytes ▶ Improved sensitivity for low LODs/LOQs ▶ Identification/confirmation ▶ Cell accelerator voltage (CAV) ▶ ESI source conditions ▶ Evaluate the MRMs for sensitivity and selectivity to choose +ESI Product Ion:1 (rt: 3.765-3.877 min, 6 scans) Frag=380.0V CF=0.000 DF=0.000 (311.1000 -> **) Sulfadoxin_Optimizer_5uL_P2.d x10 6 CE = 0 4 311.1000 2 0 x10 6 156.0000 108.2000 +ESI Product Ion:2 (rt: 3.770-3.882 min, 6 scans) Frag=380.0V CF=0.000 DF=0.000 [email protected] (311.1000 -> **) Sulfadoxin_Optimizer_5uL_P2.d CE = 15 3 2 Challenges – Water and acetonitrile solvent mixture – Ratio between aqueous and organic solvent – Addition of acid – Addition of EDTA buffer ▶ Clean-up (optional) – Hexane defatting – Modified QuEChERS (dSPE) – Supported liquid extraction (SLE) – Enhanced Matrix Removal-Lipid (EMR) – SPE Ratio of Extraction Solvent 311.2000 140.2000 65.1000 +ESI Product Ion:3 (rt: 3.774-3.886 min, 6 scans) Frag=380.0V CF=0.000 DF=0.000 [email protected] (311.1000 -> **) Sulfadoxin_Optimizer_5uL_P2.d 245.0000 218.0000 CE = 30 1.5 1 ▶ A large spectrum of drug classes ▶ Parent drugs and metabolites ▶ Different physical/chemical properties 107.9000 92.0000 0 ▶ Extraction 156.1000 1 x10 6 Sample Preparation 92.0000 108.1000 156.1000 140.1000 65.2000 80.3000 +ESI Product Ion:4 (rt: 3.779-3.891 min, 6 scans) Frag=380.0V CF=0.000 DF=0.000 [email protected] (311.1000 -> **) Sulfadoxin_Optimizer_5uL_P2.d 0.5 0 x10 5 5 64.9000 2.5 – Hydrophilic to hydrophobic – Acidic, neutral and basic – Stability – Interaction with matrix components ▶ Compromise between analyte scope and performance characteristics ▶ Matrix effects and potential interference from co-extractives Matrices of Interest for Our Method Development ▶ Infant formula and its relevant ingredients Veterinary Drugs of Interest for Our Method Development Total Numbers of Interest 0 x10 5 92.0000 230.0000 CE = 45 154.1000 201.2000 CE = 60 80.2000 53.1000 50 60 70 80 90 100 110 120 132.1000 130 140 150 154.2000 160 170 180 190 200 210 220 230 240 250 260 270 280 290 ▶ 102 analytes, 9 sub-classes ▶ Aminoglycoside (7, analyzed in separate method), Amphenicol (5), Beta Lactom-cephalosporin (12), Beta lactam-penicillin (8), Macrolides and lincosamides (12), Other (9), Quinolones (16), Sulfonamides (24), Tetracyclines (9) Structures of Representative Antibiotics and Other Drugs Streptomycin (Aminoglycoside) Florfenicol amine (Amphenicol) Ceftiofur (Cephalosporin) MF C21H39N7O12 MW=581.57 MF C10H14FNO3S MW=247.291 MF C19H17N5O7S3 MW=523.56 320 Note: 0.1% formic acid added to ACN to assist with protein precipitation ▶ Anthelmintic (Mix A-22) ▶ Beta lactam of cephalosporin and penicillin (antibiotic) (Mix B-20) ▶ Macrolides and lincosamides (antibiotic) (Mix C-13) ▶ Quinolones and others (antibiotic) (Mix D-23) ▶ Sulfonamides (antibiotic) (Mix E-24) ▶ Tetracyclines (antibiotic) (Mix F-9) ▶ Beta agonists, coccidiostat, and antimicrobial growth promoter Spike recovery of 60-130% for the majority of analytes/classes Lower spike recoveries (<60%) for tetracycline and some quinolones Addition of EDTA Buffer Aqueous EDTA buffer 0.05M EDTA 0.025M EDTA 0.1M EDTA 0.1M EDTA0.05M succinate ▶ To improve the elution profile ▶ To reduce potential interferences between compounds ▶ To separate compounds, which share the same precursor and even Majority of analytes/classes maintained spike recovery of 60-130% LC Conditions Tetracyclines improved spike recoveries from 0-15% to 60-85% product ions ▶ Column: C18 ▶ Column temperature: 40oC ▶ Flow rate: 0.5 mL/min ▶ Injection volume: 5 µL Agilent® Zorbax® Eclipse® Mobile Phase A Mobile Phase B 0.1M EDTAMcIlvaine Plus, 2.1x100 mm, 1.8 μm Problematic quinolones improved spike recoveries from 50-60 % to 70-120% Initial Mobile Phases and Gradients Gradient Antibiotics 310 Analytes in Positive Mode (~150) Divided into 9 Groups Optimization of LC Conditions Antibiotic 300 Counts vs. Mass-to-Charge (m/z) Multi-Class Antiprotozoal (1), Beta agonist (8), Coccidiostat (10), Dye (5), NSAID (1), Other-no class (1), Pesticide (2) and Tranquilizer (5) 1:1 water - ACN 1:3 water - ACN 107.9000 ▶ 161 veterinary drug analytes and 10 internal standards ▶ All the analytes included to cover for the needs of global regulation ▶ 11 classes ▶ Anthelmintic (23), Antibiotic (102), Antimicrobial Growth Promoter (3), Two steps: 1:1 water - ACN followed by 1:1 extract dilution with ACN 65.2000 (Mix G-22) ▶ Tranquilizers, Dyes and Pesticides (Mix H-12) ▶ Amphenicol, aminoglycoside, and other (antibiotic) (Mix I-4) and different government monitoring programs Aqueous to organic solvent ratio 245.2000 108.2000 80.1000 126.1000 58.0000 184.2000 +ESI Product Ion:5 (rt: 3.783-3.895 min, 6 scans) Frag=380.0V CF=0.000 DF=0.000 [email protected] (311.1000 -> **) Sulfadoxin_Optimizer_5uL_P2.d 5 0 212.1000 Optimum Mobile Phases and Gradients 0.1% formic acid in water 0.1% formic acid in acetonitrile Sample Preparation General Procedure 0.1% formic acid in water 0.1% formic acid in methanol Min %A %B Min %A %B 0 0.5 9 11 11.1 17 98 98 10 10 98 98 2 2 90 90 2 2 0 0.75 7 11 13 13.1 17 98 98 60 0 0 98 98 2 2 40 100 100 2 2 Weigh 2 g sample Add internal standard mix Add 10 mL 0.05M EDTA buffer in water, shake to homogeneous Add 10 mL 0.1% formic acid in acetonitrile, shake 5 minutes Centrifuge 5 minutes Clean-up (optional) Amoxicillin (Penicillin) MF C16H19N3O5S MW=365.4 Tylosin A (Macrolide) Lincomycin (Lincosamide) MF C46H77NO17 MW=915.52 MF C18H34N2O6S MW=406.21 Elution Profile Comparison for All Analytes Reconstitute in 3:1 (v/v) water-acetonitrile LC-MS/MS analysis Initial Ciprofloxacin (Quinolone) MF C17H18FN3O3 MW=331.34 Sulfamethizole (Sulfonamide) MF C9H10N4O2S2 MW=270.02 Next Steps Trimethoprim (other) ▶ Evaluate the extraction procedure in other relevant matrices ▶ Evaluate short-term and long-term effects of clean-up ▶ Determine analyte stability in standard mixtures and sample extracts MF C14H18N4O3 MW=262.22 Other Drugs Cambendazole (Anthelmintic) Ractopamine (β-agonist) Ipronidazole (Coccidiostat-nitroimidazole) MF C14H14N4O2S MW=302.35 MF C18H23NO3 MW=301.17 MF C7H11N3O2 MW=169.09 Decoquinate (Coccidiostat) MF C24H35NO5 MW=417.54 Malachite Green (Dye) Chlorpromazine (Tranquilizer) MF C23H25ClN2 MW=364.91 MF C17H19ClN2S MW=318.10 Virginiamycin (M1) (Antimicrobial Growth Promoter) Strychnine (Pesticide) Isometamidium (Antiprotozoal) MF C28H35N3O7 MW=525.59 MF C21H22N2O2 MW=334.41 MF C28H25N7 MW=460.55 Presented at RAFA 2015 Optimized References Robert C., Gillard N., Brasseur P. Y., Pierret G., Ralet N., Dubois M., and Delahaut Ph., “Rapid multi-residue and multi-class qualitative screening for veterinary drugs in foods of animal origin by UHPLC-MS/MS”, Food Additives and Contaminants, Part A 30(3):443-457 (2013). Kaufmann A., Butcher P., Maden K., Walker S., and Widmer M., “Multi-residue quantification of veterinary drugs in milk with a novel extraction and cleanup technique: Salting out supported liquid extraction (SOSLE)”, Analytical Chimica Acta 820:56-68 (2014).